SlideShare a Scribd company logo
NAFLD ꝏ METABOLIC
SYNDROME
DR.S.VADIVEL KUMARAN
MD(Gen.Med).,DM(Med.Gastro)
Kauvery Hospital
Alwarpet-Chennai
NAFLD
It’s a clinico-histopathologic infirmity
Hepatic pandemic of 21st century
Definitions
Shutterstock ID: 286407365
Fat Deposition in
Liver
The
macrovesicular
steatosis that
occupies at least
5% of the
hepatocytes
Simple Steatosis
Presence of fat in
the liver with or
without the
presence of lobular
inflammation on
histology
Non-alcoholic Steatohepatitis or NASH
Steatosis and inflammation are associated with the
presence of one of the following 3 additional features
on liver histology:
Ballooning of hepatocytes
Mallory hyaline bodies
Fibrosis
Duseja J, et al. J Clin Exp Hepatol. 2015;5(1):51-68.
SYNONYMS
Alcohol-like liver hepatitis
Steatonecrosis
Pseudo-alcoholic hepatitis
Fatty liver hepatitis
Diabetic hepatitis
Non-alcoholic fatty liver disease
NAFLD is probably the most common liver
disease in many countries affecting 10%
to 24% of the general population.
There is a direct correlation between body
mass index (BMI) and prevalence and
severity of NAFLD.
Annals of hepatology 2002; 1(1): January-March: 12-19
MORBIDITY
Globally- 25-30%
India- 9-32%: Age group of 40-60yrs.
Aetiopathogenic Factors
Family history
PNPLA3 & BMP6
Risk Factors of
NAFLD
Calzadilla Bertot L, et al. Int J Mol Sci. 2016;17(5):774.
NAFLD, non-alcoholic fatty liver disease;
NASH, non-alcoholic steatohepatitis.
Source: Patel V, 2016.
NASH Association
Diabetes
Metabolic syndrome
Atherogenic dyslipidemia
CAD
CKD
HCC
“Two hit or Multiple hit”
OXIDATIVE STRESSORS
Hepatic iron
Antioxidant deficiency
Leptin(↑)
Altered gut microbes
NAFLD
No longer a NASCENT finding
Prevalence in Asian
Countries
Prevalence (%) of NAFLD in different Asian
countries are as follows1:
Prevalence of NASH in patients with biopsy-proven
NAFLD is 63.5%3
China 15%-40%
India 30%
Japan 25%-30%
Korea 27%
Affects around a quarter of the Asian adult population.1
NAFLD
epidemic in
Asia1,2
Obesity
Metabolic
syndrome
Urbanisation
Sedentary
lifestyle
Western diet
1. Fan JG, et al. J Hepatol. 2017;67(4):862-873.
2. Pati GK, et al. Euroasian J Hepatogastroenterol. 2016;6(2):154-162.
3. Younossi ZM, et al. Hepatology. 2016;64(1):73-84.
NAFLD, non-alcoholic fatty liver
disease; NASH, non-alcoholic
steatohepatitis.
POPULAION 100%
NAFL 30%
NASH 7%
NASH Cirrhosis 9-25%
Liver failure 40-62%
HCC 4-22%,
Liver mortality
30-40%
Improves- 15-25%
Stable – 34-50%
HCC- 0-0.5%
Stable- 50-70%
Progress- 25-37%
HCC- 0-2.8%
INDIAN SCENARIO
NAFLD
9-32%
NASH
FIBROSIS
ESLD
HCC
25%
41%
5.4%
2-3%
NAFLD:
30-80% of obese individuals
30-50% of diabetics
90% of hyperlipidemics
NAFLD-Metabolic Syndrome- THE LINK
NAFLD-Metabolic Syndrome- THE LINK
International Diabetes Federation Definition:
Abdominal obesity plus two other components: elevated
BP, low HDL, elevated TG, or impaired fasting glucose
Definition
Constellation of metabolic abnormalities
that confer increased risk of cardiovascular
disease(CVD) and diabetes mellitus.
Alternative names
Metabolic syndrome
Syndrome X
Insulin resistance syndrome
Deadly quartet
Reaven’s syndrome
THE METABOLIC SYNDROME
HYPERTENSION
TYPE II
DIABETES MELLITUS
ATHEROSCLEROSIS
INSULIN
RESISTANCE
DYSLIPIDEMIA
Steatohepatitis..
IDF criteria
1. Waist circumference: ≥90 in males ≥80 in
females
2. Plus two or more of the following
a) Hypertriglyceridemia: ≥150 TG’s or specific medication
b) Low HDL cholesterol: <40(M) and <50(F) or specific
medication
c) Hypertension: blood pressure ≥130 mm systolic or ≥85
mm diastolic or specific medication
d) Fasting plasma glucose: ≥100 mg/dl or specific
medication or previously diagnosed T2DM
20 – 30 % of population in
economically advanced
countries, but…
Only 5 % in those with normal
BMI;
22 % of overweighted patients
60 % of patients with obesity
Metabolic syndrome today
Obesity - a major ethiologic factor
in NAFLD
The prevalence of fatty liver in the general population is
about 23%
The prevalence among alcoholics reaches 46%, among
the obese - 95%, and among alcoholics who are
overweight - 76%
Consequently, fatty liver is caused by obesity in a
greater extent than by alcohol
1. Drapkina OM, Smirin VI, VT Ivashkin Nonalcoholic fatty liver disease - a modernapproach to the problem. Attending Doctor. 2010. Т. 5. # 5. pg.
57–61.
2. Drapkina OM, Smirin VI, VT Ivashkin Pathogenesis, treatment and epidemiology ofNAFLD - what's new? Epidemiology of NAFLD in Russia.
RMJ. 2011; 28: 1717-1722
Increase in liver free fatty acids inflow (VLDL )
Glucose utilization in peripheral tissues  … 
hyperinsulinemia
SMC proliferation with phenotypic changes
Fasting hypertriglyceridemia
 HDL, LDL
Visceral obesity
Lipoprotein Structure
Apolipoprotein
Free
cholesterol
Cholesterol esters
Triglycerides
Phospholipids
Liver is a major target of injury in patients with MS
Liver in metabolic syndrome
American Journal of the Medical Sciences. 330(6):326-335, Dec 2005.
Insulin resistance (≈ 30 % of adults)
Fat accumulation into hepatocytes (gluconeogenesis,
glycogenolysis)
Nonalcoholic steatohepatitis
Nonalcoholic fatty liver disease (up to 20 % of adults)
cirrhosis and end-stage liver disease
NAFLD-Metabolic Syndrome- THE LINK
NAFLD-Metabolic Syndrome- THE LINK
NAFLD-Metabolic Syndrome- THE LINK
Pathogenesis contd…
Impaired insulin
mediated
glucose uptake
Toxic injury to
pancreatic
islets
Increased
insulin
resistance
Hyperglycemia Type 2 DM
Insulin
resistance
pp/fasting
hyperinsulinemia
Lipolysis by
LPL
Abundance of
FFA’s
Nonalcoholic steatohepatitis:
Morphology
CMAJ 2005;172(7):899-905
Gut microbiota :Pathogenesis of
NAFLD
(1)Increased production and absorption of gut short-
chain fatty acids
(2)Altered dietary choline metabolism by the microbiota
(3)Altered bile acid pools by the microbiota
(4)Increased delivery of microbiota derived ethanol to
liver
(5)Gut permeability alterations and release of endotoxin
(6)Interaction between specific diet and microbiota
March
33
LEAN NASH
• The pathophysiology may be quite different.
• Genetic predispositions, fructose- and cholesterol-
rich diet, visceral adiposity and dyslipidaemia.
• Risk for metabolic disturbances, cardiovascular
morbidity or overall mortality.
• Secondary causes to be ruled out
• The effectiveness of exercise and
pharmacotherapy-not known.
• Weight loss is expected to help in visceral obesity
• Further investigation is needed- mechanistic
pathogenesis, risk assessment, natural history and
therapeutic approach
March
34
The Liver-Heart Connection
NAFLD - a chronic inflammatory
process
There is a correlation between levels of CRP
and IL-6 and the degree of inflammation
and fibrosis in NAFLD
Wieckowska A et al. Am J Gastroenterol 2008;103:1372–1379
Noninvasive Imaging of
Steatosis
Abdominal ultrasound1,2
First-line investigation for patients with suspected hepatic
steatosis
Qualitative assessment of fatty infiltration of liver
Presence of >33% fat on liver biopsy, optimal for detection
of steatosis by ultrasound
Characteristic sonographic features3: Attenuation
of image quickly within 4 to 5 cm of depth, making
deeper structures, difficult to decipher
• Echogenic diffusely but particularly important to
note brightness within the first 2 to 3 cm of depth
• Liver is uniformly heterogeneous
• Thick subcutaneous depth (>2 cm)
• Liver fills entire field with no edges visible
(viewed as helpful but not necessary for
diagnosis)
Simple noninvasive tests of
fibrosis
• NAFLD fibrosis score: age,
hyperglycaemia, body mass
index, platelet count, albumin,
AST/ALT ratio
• BARD score: body mass index,
AST/ALT ratio, type 2 diabetes
mellitus
• FIB-4 score: age, AST, ALT
Serum Biomarkers
• Biomarkers can be used in differentiating simple
steatosis from NASH1
• But, biomarkers are still under evaluation1
• Potential biomarkers: cytokeratin-18 and terminal
peptide of procollagen III1
NASH, non-alcoholic
steatohepatitis.
1. Dyson JK, et al. Frontline Gastroenterol. 2014;5(3):211-218.
2. J Hepatol. 2016;64(6):1388-1402.
Stock photo ID: 615791984
Serum biomarkers can be an acceptable alternative for diagnosis of steatosis
when imaging modalities are not available.2
TREATMENT
Weight reduction- include a combination of caloric restriction,
increased physical activity, and behavior modification.
LIFESTYLE MODIFICATIONS
What to do..?
~500 kcal restriction daily equates to weight reduction of 0.45Kg
per week.
Diets restricted in carbohydrate typically provide a rapid initial
weight loss.
Adherence to the diet is more important than which diet is chosen.
A high-quality diet— i.e., enriched in fruits, vegetables, whole
grains, lean poultry, and fish—should be encouraged to provide
the maximum overall health benefit.
DIET---
PHYSICAL ACTIVITY-
60–90 min of daily activity (At least 30 min.) Gradual increases in physical activity
should be encouraged to enhance adherence and avoid injury.
Some high-risk patients should undergo formal cardiovascular evaluation before
initiating an exercise program.
Physical activity could be formal exercise such as jogging, swimming, or tennis or
routine activities, such as gardening, walking, and housecleaning.
Role of LSM in NAFLD
LSM IS THE CORNERSTONE OF NAFLD MANAGEMENT
EXERCISE AND
CALORIC
RESTRICTION
INDUCING
WEIGHT LOSS
ARE NEEDED TO
IMPROVE NAFLD
Appetite suppressants-
phentermine and
sibutramine.
Absorption inhibitors-
Orlistat
Bariatric surgery is also
an option for patients
with BMI >40 kg/m2
or >35 kg/m2 with
comorbidities.
OBESITY
Statins and NAFLD
Safety: ↑ AST / ALT in 1-3% of patients
There are no convincing data on the relationship
between ↑ AST / ALT and histologically verified liver
damage against statins
Atorvastatin (80 mg) reduced the AST / ALT,
and possibly reduced steatosis[Gomez-Dominguez, 2006;
Kiyici, 2003]
Pravastatin (80 mg) reduced ALT [Lewis et al. 2007]
Possible mechanisms
- Reduction of TNF-alpha, IL-6, CRP,
- Reduced delivery of FFA to the liver, the effect on insulin
through adiponectin
Statins for NAFLD: molecular mechanisms
Argo C.K., Loria P., Statins in liver disease: a molehill,
an iceberg, or neither? // Hepatology. 2008 Aug;48(2):662–9.
• Effect on the metabolism of the
gene sonic hedgehog (sHh) -
progression of fibrosis
and reparative mechanisms
• Inhibition of sHh reduces weight
gain from dietary habits
• sHh: effects on stellate cells
and possible involvement in the
pathogenesis of Cirrhosis sonic hedgehog
A Fasting triglyceride value of <150 mg/dL is recommended. A
weight reduction of >10% is necessary to lower fasting
triglycerides.
A fibrate (gemfibrozil or fenofibrate) is the drug of choice to
lower fasting triglycerides and typically achieve a 35–50%
reduction.
Other drugs that lower triglycerides include statins, nicotinic
acid, and high doses of omega-3 fatty acids.
TRIGLYCERIDES
For rise in HDL cholesterol, weight reduction is an important
strategy.
Nicotinic acid is the only currently available drug with
predictable HDL cholesterol-raising properties.
Statins, fibrates, and bile acid sequestrants have modest effects
(5–10%), and there is no effect on HDL cholesterol with
ezetimibe or omega-3 fatty acids.
HDL Cholesterol
• OCA
• Lubiprostone
• DMR- Procedure
• DPP4
• Saroglitazar
• Elafibrinor
• Empagliflozin
• Fecal Microbiota Transplantation
• Current and Potential future drugs
Newer approaches
New
approaches
in NAFLD
drug
therapy
Journal of
Hepatology 2018
vol. 68 j 362–375
New therapeutic strategies in
nonalcoholic fatty liver disease: a focus
on promising drugs for nonalcoholic
steatohepatitis
New therapeutic strategies in nonalcoholic fatty liver disease: a focus
on promising drugs for nonalcoholic steatohepatitis
Natalia Pydyn 2020
NAFLD-Metabolic Syndrome- THE LINK
NAFLD-Metabolic Syndrome- THE LINK
Effects of Interventions in NAFLD
Weight
Loss
Insulin
Resista
nce
Liver
Enzymes
Inflam
matio
n
Fibrosis
Lifestyle
interventions
Yes Yes Yes Yes Unproven
Vitamin E No No Yes Yes No
Pioglitazone Weight
gain
Yes Yes Yes Might be
beneficial
Ursodeoxychol
ic acid
No Yes Yes Yes Might be
beneficial
Metformin Yes Yes No No No
Gitto S, et al. Gastroenterol Res Pract. 2015;2015:732870.
NAFLD-Metabolic Syndrome- THE LINK

More Related Content

PDF
MAFLD, a new name of an old disease
PPTX
Dyslipidemia
PPTX
SGLT2I The paradigm change in diabetes management
PPTX
Dyslipidaemia presentation
PPTX
Non alcoholic fatty liver disease(NAFLD)
PPTX
Diabetic dyslipidemia
PPTX
Dyslipidemia
MAFLD, a new name of an old disease
Dyslipidemia
SGLT2I The paradigm change in diabetes management
Dyslipidaemia presentation
Non alcoholic fatty liver disease(NAFLD)
Diabetic dyslipidemia
Dyslipidemia

What's hot (20)

PPTX
Metabolic syndrome & its complications
PPTX
Nonalcoholic fatty liver disease
PPTX
Newer OHA and insulin
PPTX
Dyslipdemia Guidelines Head to Head
PPTX
Non-Alcoholic Fatty Liver Disease (NAFLD)
PPT
NAFLD, NASH
PPTX
Management of dyslipidemia
PPT
dyslipidemia6.ppt
PPTX
Individualized Diabetes treatment in Indian scenario
PPTX
Diabetes mellitus 2019 final
PPTX
PPTX
Non alcoholic fatty liver disease: what can we do about it?
PPT
PPTX
Diabetic dyslipidemia
PPTX
metabolic dysfunction associated steatotic liver disease -1.pptx
PDF
Hyperlipidaemia
PPTX
Dapagliflozin- a novel SGLT2 inhibitor
PPT
DYSLIPIDEMIA 2022.ppt
PPTX
Metabolic Associated Fatty Liver Disease (MAFLD) for General Practitioners of...
PPTX
Hyperlipidemia
Metabolic syndrome & its complications
Nonalcoholic fatty liver disease
Newer OHA and insulin
Dyslipdemia Guidelines Head to Head
Non-Alcoholic Fatty Liver Disease (NAFLD)
NAFLD, NASH
Management of dyslipidemia
dyslipidemia6.ppt
Individualized Diabetes treatment in Indian scenario
Diabetes mellitus 2019 final
Non alcoholic fatty liver disease: what can we do about it?
Diabetic dyslipidemia
metabolic dysfunction associated steatotic liver disease -1.pptx
Hyperlipidaemia
Dapagliflozin- a novel SGLT2 inhibitor
DYSLIPIDEMIA 2022.ppt
Metabolic Associated Fatty Liver Disease (MAFLD) for General Practitioners of...
Hyperlipidemia
Ad

Similar to NAFLD-Metabolic Syndrome- THE LINK (20)

PPTX
NAFLD non alcoholic fatty liver disease.pptx
PPTX
GIT J Club: NAFLD.
PPTX
NASH risk factors and management.pptx
PPTX
NAFLD-1.pptx internal medicine scoreee in
PPTX
Nonalcoholic fatty liver disease
PPTX
Non alcoholic fatty liver disease
PPTX
NON ALCOHOLIC FATTY LIVER DISEASES modify (edited by Kyin).pptx
PPTX
metabolic dysfunction associated steatotic liver disease.pptx
PPTX
Update on NAFLD NASH.pptx
PPT
Non-Alcoholic-Fatty-Liver-Disease .ppt
PDF
Non Alcoholic Fatty Liver Disease: A New Urban Epidemic.
PPTX
NAFLD A GREAT MASQUERADER A MULTI SYSTEM INVOLVEMENT -
PPTX
NAFLD.pptx
PPTX
Non alcoholic fatty liver disease presentation
PPTX
NAFLD
PPTX
Fatty Liver.pptx on essential information of Fatty Liver
PPTX
Non Alcoholic Fatty Liver Disease
PPTX
Interplay between Obesity and Liver Disease
NAFLD non alcoholic fatty liver disease.pptx
GIT J Club: NAFLD.
NASH risk factors and management.pptx
NAFLD-1.pptx internal medicine scoreee in
Nonalcoholic fatty liver disease
Non alcoholic fatty liver disease
NON ALCOHOLIC FATTY LIVER DISEASES modify (edited by Kyin).pptx
metabolic dysfunction associated steatotic liver disease.pptx
Update on NAFLD NASH.pptx
Non-Alcoholic-Fatty-Liver-Disease .ppt
Non Alcoholic Fatty Liver Disease: A New Urban Epidemic.
NAFLD A GREAT MASQUERADER A MULTI SYSTEM INVOLVEMENT -
NAFLD.pptx
Non alcoholic fatty liver disease presentation
NAFLD
Fatty Liver.pptx on essential information of Fatty Liver
Non Alcoholic Fatty Liver Disease
Interplay between Obesity and Liver Disease
Ad

More from Vadivel Kumaran Sivasankaran (18)

PPTX
Treat to Target approach to Ulcerative Colitis Treatment_v2.pptx
PPTX
Inflammatory Bowel Disease-Flares & Management
PPTX
Steroids in UC.pptx
PPTX
Budesonide MMX SEC.pptx
PPTX
Irritable bowel syndrome (IBS)-Dr.S.Vadivel Kumaran.,MD(Gen.Med).,DM(Med.Gastro)
PPTX
Evaluation of cirrhosis
PPTX
Viral hepatitis-Doctors awareness
PPTX
Ercp- for Beginners
PPTX
Pyloric gland metaplasia of ileum-Crohns disease
PPTX
PPTX
Functional dyspepsia-Approach
PPTX
PPI when and where
PPTX
DIABETES AND GASTROINTESTINAL TRACT
PPTX
DIABETES AND GASTROINTESTINAL TRACT
PPTX
PPTX
Treat to Target approach to Ulcerative Colitis Treatment_v2.pptx
Inflammatory Bowel Disease-Flares & Management
Steroids in UC.pptx
Budesonide MMX SEC.pptx
Irritable bowel syndrome (IBS)-Dr.S.Vadivel Kumaran.,MD(Gen.Med).,DM(Med.Gastro)
Evaluation of cirrhosis
Viral hepatitis-Doctors awareness
Ercp- for Beginners
Pyloric gland metaplasia of ileum-Crohns disease
Functional dyspepsia-Approach
PPI when and where
DIABETES AND GASTROINTESTINAL TRACT
DIABETES AND GASTROINTESTINAL TRACT

Recently uploaded (20)

PPTX
First Aid and Basic Life Support Training.pptx
PPTX
PEDIATRIC OSCE, MBBS, by Dr. Sangit Chhantyal(IOM)..pptx
PPTX
different types of Gait in orthopaedic injuries
PPTX
Medical aspects of impairment including all the domains mentioned in ICF
PPT
KULIAH UG WANITA Prof Endang 121110 (1).ppt
PPT
Microscope is an instrument that makes an enlarged image of a small object, t...
PPTX
General Pharmacology by Nandini Ratne, Nagpur College of Pharmacy, Hingna Roa...
PDF
Khaled Sary- Trailblazers of Transformation Middle East's 5 Most Inspiring Le...
PPTX
Basics of pharmacology (Pharmacology I).pptx
PPTX
CBT FOR OCD TREATMENT WITHOUT MEDICATION
PPTX
BLS, BCLS Module-A life saving procedure
PPTX
1. Drug Distribution System.pptt b pharmacy
PPTX
3. Adherance Complianace.pptx pharmacy pci
PPT
Recent advances in Diagnosis of Autoimmune Disorders
PPTX
Vaginal Bleeding and Uterine Fibroids p
PPTX
Trichuris trichiura infection
PDF
Priorities Critical Care Nursing 7th Edition by Urden Stacy Lough Test Bank.pdf
PDF
MINERAL & VITAMIN CHARTS fggfdtujhfd.pdf
PDF
2E-Learning-Together...PICS-PCISF con.pdf
PPTX
Nancy Caroline Emergency Paramedic Chapter 8
First Aid and Basic Life Support Training.pptx
PEDIATRIC OSCE, MBBS, by Dr. Sangit Chhantyal(IOM)..pptx
different types of Gait in orthopaedic injuries
Medical aspects of impairment including all the domains mentioned in ICF
KULIAH UG WANITA Prof Endang 121110 (1).ppt
Microscope is an instrument that makes an enlarged image of a small object, t...
General Pharmacology by Nandini Ratne, Nagpur College of Pharmacy, Hingna Roa...
Khaled Sary- Trailblazers of Transformation Middle East's 5 Most Inspiring Le...
Basics of pharmacology (Pharmacology I).pptx
CBT FOR OCD TREATMENT WITHOUT MEDICATION
BLS, BCLS Module-A life saving procedure
1. Drug Distribution System.pptt b pharmacy
3. Adherance Complianace.pptx pharmacy pci
Recent advances in Diagnosis of Autoimmune Disorders
Vaginal Bleeding and Uterine Fibroids p
Trichuris trichiura infection
Priorities Critical Care Nursing 7th Edition by Urden Stacy Lough Test Bank.pdf
MINERAL & VITAMIN CHARTS fggfdtujhfd.pdf
2E-Learning-Together...PICS-PCISF con.pdf
Nancy Caroline Emergency Paramedic Chapter 8

NAFLD-Metabolic Syndrome- THE LINK

  • 1. NAFLD ꝏ METABOLIC SYNDROME DR.S.VADIVEL KUMARAN MD(Gen.Med).,DM(Med.Gastro) Kauvery Hospital Alwarpet-Chennai
  • 2. NAFLD It’s a clinico-histopathologic infirmity Hepatic pandemic of 21st century
  • 3. Definitions Shutterstock ID: 286407365 Fat Deposition in Liver The macrovesicular steatosis that occupies at least 5% of the hepatocytes Simple Steatosis Presence of fat in the liver with or without the presence of lobular inflammation on histology Non-alcoholic Steatohepatitis or NASH Steatosis and inflammation are associated with the presence of one of the following 3 additional features on liver histology: Ballooning of hepatocytes Mallory hyaline bodies Fibrosis Duseja J, et al. J Clin Exp Hepatol. 2015;5(1):51-68.
  • 4. SYNONYMS Alcohol-like liver hepatitis Steatonecrosis Pseudo-alcoholic hepatitis Fatty liver hepatitis Diabetic hepatitis
  • 5. Non-alcoholic fatty liver disease NAFLD is probably the most common liver disease in many countries affecting 10% to 24% of the general population. There is a direct correlation between body mass index (BMI) and prevalence and severity of NAFLD. Annals of hepatology 2002; 1(1): January-March: 12-19
  • 8. Risk Factors of NAFLD Calzadilla Bertot L, et al. Int J Mol Sci. 2016;17(5):774. NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis. Source: Patel V, 2016.
  • 9. NASH Association Diabetes Metabolic syndrome Atherogenic dyslipidemia CAD CKD HCC “Two hit or Multiple hit”
  • 10. OXIDATIVE STRESSORS Hepatic iron Antioxidant deficiency Leptin(↑) Altered gut microbes
  • 11. NAFLD No longer a NASCENT finding
  • 12. Prevalence in Asian Countries Prevalence (%) of NAFLD in different Asian countries are as follows1: Prevalence of NASH in patients with biopsy-proven NAFLD is 63.5%3 China 15%-40% India 30% Japan 25%-30% Korea 27% Affects around a quarter of the Asian adult population.1 NAFLD epidemic in Asia1,2 Obesity Metabolic syndrome Urbanisation Sedentary lifestyle Western diet 1. Fan JG, et al. J Hepatol. 2017;67(4):862-873. 2. Pati GK, et al. Euroasian J Hepatogastroenterol. 2016;6(2):154-162. 3. Younossi ZM, et al. Hepatology. 2016;64(1):73-84. NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis.
  • 13. POPULAION 100% NAFL 30% NASH 7% NASH Cirrhosis 9-25% Liver failure 40-62% HCC 4-22%, Liver mortality 30-40% Improves- 15-25% Stable – 34-50% HCC- 0-0.5% Stable- 50-70% Progress- 25-37% HCC- 0-2.8%
  • 15. NAFLD: 30-80% of obese individuals 30-50% of diabetics 90% of hyperlipidemics
  • 18. International Diabetes Federation Definition: Abdominal obesity plus two other components: elevated BP, low HDL, elevated TG, or impaired fasting glucose
  • 19. Definition Constellation of metabolic abnormalities that confer increased risk of cardiovascular disease(CVD) and diabetes mellitus.
  • 20. Alternative names Metabolic syndrome Syndrome X Insulin resistance syndrome Deadly quartet Reaven’s syndrome
  • 21. THE METABOLIC SYNDROME HYPERTENSION TYPE II DIABETES MELLITUS ATHEROSCLEROSIS INSULIN RESISTANCE DYSLIPIDEMIA Steatohepatitis..
  • 22. IDF criteria 1. Waist circumference: ≥90 in males ≥80 in females 2. Plus two or more of the following a) Hypertriglyceridemia: ≥150 TG’s or specific medication b) Low HDL cholesterol: <40(M) and <50(F) or specific medication c) Hypertension: blood pressure ≥130 mm systolic or ≥85 mm diastolic or specific medication d) Fasting plasma glucose: ≥100 mg/dl or specific medication or previously diagnosed T2DM
  • 23. 20 – 30 % of population in economically advanced countries, but… Only 5 % in those with normal BMI; 22 % of overweighted patients 60 % of patients with obesity Metabolic syndrome today
  • 24. Obesity - a major ethiologic factor in NAFLD The prevalence of fatty liver in the general population is about 23% The prevalence among alcoholics reaches 46%, among the obese - 95%, and among alcoholics who are overweight - 76% Consequently, fatty liver is caused by obesity in a greater extent than by alcohol 1. Drapkina OM, Smirin VI, VT Ivashkin Nonalcoholic fatty liver disease - a modernapproach to the problem. Attending Doctor. 2010. Т. 5. # 5. pg. 57–61. 2. Drapkina OM, Smirin VI, VT Ivashkin Pathogenesis, treatment and epidemiology ofNAFLD - what's new? Epidemiology of NAFLD in Russia. RMJ. 2011; 28: 1717-1722
  • 25. Increase in liver free fatty acids inflow (VLDL ) Glucose utilization in peripheral tissues  …  hyperinsulinemia SMC proliferation with phenotypic changes Fasting hypertriglyceridemia  HDL, LDL Visceral obesity
  • 27. Liver is a major target of injury in patients with MS Liver in metabolic syndrome American Journal of the Medical Sciences. 330(6):326-335, Dec 2005. Insulin resistance (≈ 30 % of adults) Fat accumulation into hepatocytes (gluconeogenesis, glycogenolysis) Nonalcoholic steatohepatitis Nonalcoholic fatty liver disease (up to 20 % of adults) cirrhosis and end-stage liver disease
  • 31. Pathogenesis contd… Impaired insulin mediated glucose uptake Toxic injury to pancreatic islets Increased insulin resistance Hyperglycemia Type 2 DM Insulin resistance pp/fasting hyperinsulinemia Lipolysis by LPL Abundance of FFA’s
  • 33. Gut microbiota :Pathogenesis of NAFLD (1)Increased production and absorption of gut short- chain fatty acids (2)Altered dietary choline metabolism by the microbiota (3)Altered bile acid pools by the microbiota (4)Increased delivery of microbiota derived ethanol to liver (5)Gut permeability alterations and release of endotoxin (6)Interaction between specific diet and microbiota March 33
  • 34. LEAN NASH • The pathophysiology may be quite different. • Genetic predispositions, fructose- and cholesterol- rich diet, visceral adiposity and dyslipidaemia. • Risk for metabolic disturbances, cardiovascular morbidity or overall mortality. • Secondary causes to be ruled out • The effectiveness of exercise and pharmacotherapy-not known. • Weight loss is expected to help in visceral obesity • Further investigation is needed- mechanistic pathogenesis, risk assessment, natural history and therapeutic approach March 34
  • 36. NAFLD - a chronic inflammatory process There is a correlation between levels of CRP and IL-6 and the degree of inflammation and fibrosis in NAFLD Wieckowska A et al. Am J Gastroenterol 2008;103:1372–1379
  • 37. Noninvasive Imaging of Steatosis Abdominal ultrasound1,2 First-line investigation for patients with suspected hepatic steatosis Qualitative assessment of fatty infiltration of liver Presence of >33% fat on liver biopsy, optimal for detection of steatosis by ultrasound Characteristic sonographic features3: Attenuation of image quickly within 4 to 5 cm of depth, making deeper structures, difficult to decipher • Echogenic diffusely but particularly important to note brightness within the first 2 to 3 cm of depth • Liver is uniformly heterogeneous • Thick subcutaneous depth (>2 cm) • Liver fills entire field with no edges visible (viewed as helpful but not necessary for diagnosis)
  • 38. Simple noninvasive tests of fibrosis • NAFLD fibrosis score: age, hyperglycaemia, body mass index, platelet count, albumin, AST/ALT ratio • BARD score: body mass index, AST/ALT ratio, type 2 diabetes mellitus • FIB-4 score: age, AST, ALT
  • 39. Serum Biomarkers • Biomarkers can be used in differentiating simple steatosis from NASH1 • But, biomarkers are still under evaluation1 • Potential biomarkers: cytokeratin-18 and terminal peptide of procollagen III1 NASH, non-alcoholic steatohepatitis. 1. Dyson JK, et al. Frontline Gastroenterol. 2014;5(3):211-218. 2. J Hepatol. 2016;64(6):1388-1402. Stock photo ID: 615791984 Serum biomarkers can be an acceptable alternative for diagnosis of steatosis when imaging modalities are not available.2
  • 41. Weight reduction- include a combination of caloric restriction, increased physical activity, and behavior modification. LIFESTYLE MODIFICATIONS
  • 43. ~500 kcal restriction daily equates to weight reduction of 0.45Kg per week. Diets restricted in carbohydrate typically provide a rapid initial weight loss. Adherence to the diet is more important than which diet is chosen. A high-quality diet— i.e., enriched in fruits, vegetables, whole grains, lean poultry, and fish—should be encouraged to provide the maximum overall health benefit. DIET---
  • 44. PHYSICAL ACTIVITY- 60–90 min of daily activity (At least 30 min.) Gradual increases in physical activity should be encouraged to enhance adherence and avoid injury. Some high-risk patients should undergo formal cardiovascular evaluation before initiating an exercise program. Physical activity could be formal exercise such as jogging, swimming, or tennis or routine activities, such as gardening, walking, and housecleaning.
  • 45. Role of LSM in NAFLD LSM IS THE CORNERSTONE OF NAFLD MANAGEMENT EXERCISE AND CALORIC RESTRICTION INDUCING WEIGHT LOSS ARE NEEDED TO IMPROVE NAFLD
  • 46. Appetite suppressants- phentermine and sibutramine. Absorption inhibitors- Orlistat Bariatric surgery is also an option for patients with BMI >40 kg/m2 or >35 kg/m2 with comorbidities. OBESITY
  • 47. Statins and NAFLD Safety: ↑ AST / ALT in 1-3% of patients There are no convincing data on the relationship between ↑ AST / ALT and histologically verified liver damage against statins Atorvastatin (80 mg) reduced the AST / ALT, and possibly reduced steatosis[Gomez-Dominguez, 2006; Kiyici, 2003] Pravastatin (80 mg) reduced ALT [Lewis et al. 2007] Possible mechanisms - Reduction of TNF-alpha, IL-6, CRP, - Reduced delivery of FFA to the liver, the effect on insulin through adiponectin
  • 48. Statins for NAFLD: molecular mechanisms Argo C.K., Loria P., Statins in liver disease: a molehill, an iceberg, or neither? // Hepatology. 2008 Aug;48(2):662–9. • Effect on the metabolism of the gene sonic hedgehog (sHh) - progression of fibrosis and reparative mechanisms • Inhibition of sHh reduces weight gain from dietary habits • sHh: effects on stellate cells and possible involvement in the pathogenesis of Cirrhosis sonic hedgehog
  • 49. A Fasting triglyceride value of <150 mg/dL is recommended. A weight reduction of >10% is necessary to lower fasting triglycerides. A fibrate (gemfibrozil or fenofibrate) is the drug of choice to lower fasting triglycerides and typically achieve a 35–50% reduction. Other drugs that lower triglycerides include statins, nicotinic acid, and high doses of omega-3 fatty acids. TRIGLYCERIDES
  • 50. For rise in HDL cholesterol, weight reduction is an important strategy. Nicotinic acid is the only currently available drug with predictable HDL cholesterol-raising properties. Statins, fibrates, and bile acid sequestrants have modest effects (5–10%), and there is no effect on HDL cholesterol with ezetimibe or omega-3 fatty acids. HDL Cholesterol
  • 51. • OCA • Lubiprostone • DMR- Procedure • DPP4 • Saroglitazar • Elafibrinor • Empagliflozin • Fecal Microbiota Transplantation • Current and Potential future drugs Newer approaches
  • 53. New therapeutic strategies in nonalcoholic fatty liver disease: a focus on promising drugs for nonalcoholic steatohepatitis New therapeutic strategies in nonalcoholic fatty liver disease: a focus on promising drugs for nonalcoholic steatohepatitis Natalia Pydyn 2020
  • 56. Effects of Interventions in NAFLD Weight Loss Insulin Resista nce Liver Enzymes Inflam matio n Fibrosis Lifestyle interventions Yes Yes Yes Yes Unproven Vitamin E No No Yes Yes No Pioglitazone Weight gain Yes Yes Yes Might be beneficial Ursodeoxychol ic acid No Yes Yes Yes Might be beneficial Metformin Yes Yes No No No Gitto S, et al. Gastroenterol Res Pract. 2015;2015:732870.